A Phase III, randomised, multicentre, parallel group, open-label, three arm study to compare the efficacy and safety of two dosing regimens of GW433908/ritonavir (700mg/100mg twice daily or 1400mg/200mg once daily ) versus lopinavir/ritonavir (400mg/100mg

    Project: Research

    Project Details

    StatusFinished
    Effective start/end date1/06/2001 → 15/10/2002

    Funding

    • GSK Glaxo Wellcome Research & Development Ltd: £5,250.00